A serotonin-norepinephrine-dopamine reuptake inhibitor originally studied as an anti-obesity agent. Promotes weight loss through appetite suppression.
Tesofensine was originally studied for neurodegenerative disease and was found to induce weight loss by reducing hunger and increasing satiety, shifting the focus toward obesity treatment.
Tesofensine is a triple monoamine reuptake inhibitor (serotonin, noradrenaline, dopamine - SNDRI) that modulates appetite, energy expenditure, and motivation.
Most weight-loss trials evaluated oral doses of 0.25, 0.5, and 1 mg/day. 0.5 mg/day showed the most balanced efficacy/tolerability; 1 mg/day produced more weight loss but more side effects.
Side effects increase with dose. Because tesofensine has a very long half-life, adverse effects may persist if the dose is too high.
Anti-Obesity Drug 9604
A synthetic peptide analog of natural AOD-9604 fragment that stimulates lipolysis and inhibits lipogenesis without affecting IGF-1 or insulin.
300 mcg5-Amino-1-Methylquinolinium
A small molecule that inhibits NNMT enzyme, boosting NAD+ levels and cellular energy. Supports fat loss and metabolic function.
1 mgIpamorelin and CJC-1295 without DAC Blend
A powerful synergistic combination of growth hormone secretagogues. Ipamorelin provides selective GH release while CJC-1295 extends GH pulse duration for enhanced fat loss and recovery.
250 mcg eachNAD+, MOTS-c, and 5-Amino-1MQ Blend
A synergistic combination targeting mitochondrial function, cellular energy, and fat metabolism. Combines NAD+ precursor with mitochondrial peptide and NNMT inhibitor for comprehensive metabolic support.
10 mg/1mg/1mg